News Release
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Corp. Reports Year to Year Revenue Increase of Over 380% and Quarter to Quarter Revenue Increase of Over 100%
Emergent Health Corp.
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today announced revenues of $373,406 for the quarter ended December 31, 2022 as compared to $185,471 for the quarter ended September 30, 2022, an increase of over 100% and revenues of $574,613 for the Year Ended December 31, 2022 as compared to $119,567 for the year ended December 31, 2021, an increase of over 380%. The financial statement can be viewed in its entirety at: https://www.otcmarkets.com/otcapi/company/financial-report/367945/content. Jim Morrison, former L'Oréal President and Emigrant’s new full time CEO stated, “The company is now engaged with several large biologics companies, and we expect enormous growth over the second and third quarter.” Emergent projects to continue increasing its revenues quarter to quarter as it expands its business internally and externally by acquisition. Recent Developments: On February 23, 2023, announced that it anticipates closing the acquisition to acquire Nanosthetic Cosmetic Labs (“Nanosthetic”) shortly. Nanosthetic, of Fort Lauderdale Florida, holds proprietary intellectual property that has been developed over the past ten years. The press release can be viewed in its entirety here. On February 21, 2023, Emergent on behalf of its subsidiary, Evolutionary Biologics, Inc., announced that it has executed a Letter of Intent to acquire a privately held company in the regenerative medical field. The company is profitable and does $5.4 Million in current revenues and projects a total of $9 Million in revenues for 2023. The press release can be viewed in its entirety here. The global biologics market size was valued at US $366.43 billion in 2021 and it is expected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGR of 7.8% from 2022 to 2030. A biologic medication is a product that is made from live organisms and contains living organism components. Examples of biologics are Recombinant protein, tissues, allergens, genes, cells, blood components, blood, and vaccinations are all examples of biologics. Examples of what can be treated are Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoid arthritis, inflammatory bowel disease, and other disorders and infections are treated with biologics. Our focus is on aesthetics cosmetics and men’s and women’s health, but also wound care and tissue regeneration. Various government efforts, higher share of biologics in the market, and rising use of biopharmaceuticals over chemically produced molecules, and many other factors are driving the biologics market expansion in the forecast period. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/
May 02, 2023 09:00 AM Eastern Daylight Time
News Release
